Vir Biotechnology Inc
NASDAQ:VIR
Vir Biotechnology Inc
NASDAQ:VIR
Price:
10
USD
5.37%
Market Cap:
$1.4B
Balance Sheet
Balance Sheet Decomposition
Vir Biotechnology Inc
Vir Biotechnology Inc
Balance Sheet Decomposition is not available for
Vir Biotechnology Inc
Vir Biotechnology Inc
Balance Sheet
Vir Biotechnology Inc
Vir Biotechnology Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
188
|
48
|
109
|
437
|
348
|
849
|
242
|
223
|
|
| Cash Equivalents |
188
|
48
|
109
|
437
|
348
|
849
|
242
|
223
|
|
| Short-Term Investments |
0
|
51
|
274
|
300
|
360
|
1 553
|
1 281
|
682
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
773
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
773
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
4
|
19
|
20
|
36
|
82
|
117
|
66
|
137
|
|
| Total Current Assets |
192
|
118
|
403
|
772
|
1 563
|
2 519
|
1 588
|
1 042
|
|
| PP&E Net |
5
|
12
|
16
|
80
|
130
|
188
|
167
|
123
|
|
| PP&E Gross |
5
|
12
|
16
|
80
|
130
|
188
|
167
|
123
|
|
| Accumulated Depreciation |
0
|
2
|
5
|
9
|
15
|
21
|
34
|
37
|
|
| Intangible Assets |
36
|
37
|
36
|
34
|
33
|
33
|
23
|
8
|
|
| Goodwill |
17
|
17
|
17
|
17
|
17
|
17
|
17
|
17
|
|
| Long-Term Investments |
0
|
0
|
24
|
0
|
201
|
24
|
105
|
190
|
|
| Other Long-Term Assets |
1
|
8
|
16
|
16
|
10
|
21
|
19
|
18
|
|
| Other Assets |
17
|
17
|
17
|
17
|
17
|
17
|
17
|
17
|
|
| Total Assets |
252
N/A
|
192
-24%
|
512
+167%
|
919
+79%
|
1 954
+113%
|
2 802
+43%
|
1 919
-32%
|
1 399
-27%
|
|
| Liabilities | |||||||||
| Accounts Payable |
5
|
7
|
6
|
5
|
7
|
6
|
6
|
5
|
|
| Accrued Liabilities |
8
|
15
|
26
|
77
|
142
|
489
|
104
|
86
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
19
|
27
|
17
|
193
|
16
|
65
|
29
|
|
| Total Current Liabilities |
12
|
40
|
59
|
99
|
341
|
511
|
175
|
120
|
|
| Long-Term Debt |
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
3
|
3
|
3
|
3
|
18
|
3
|
0
|
0
|
|
| Other Liabilities |
12
|
18
|
25
|
99
|
163
|
210
|
153
|
129
|
|
| Total Liabilities |
28
N/A
|
62
+120%
|
88
+43%
|
202
+129%
|
522
+159%
|
724
+39%
|
329
-55%
|
248
-24%
|
|
| Equity | |||||||||
| Common Stock |
293
|
309
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
78
|
194
|
369
|
667
|
139
|
377
|
238
|
760
|
|
| Additional Paid In Capital |
9
|
15
|
793
|
1 385
|
1 572
|
1 710
|
1 829
|
1 912
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
1
|
1
|
1
|
9
|
1
|
2
|
|
| Total Equity |
224
N/A
|
130
-42%
|
424
+226%
|
717
+69%
|
1 432
+100%
|
2 078
+45%
|
1 590
-23%
|
1 150
-28%
|
|
| Total Liabilities & Equity |
252
N/A
|
192
-24%
|
512
+167%
|
919
+79%
|
1 954
+113%
|
2 802
+43%
|
1 919
-32%
|
1 399
-27%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
109
|
109
|
108
|
127
|
131
|
133
|
135
|
137
|
|
Switch to:
Switch to:
See Also
Discover More
